Featured Research

from universities, journals, and other organizations

Earlier Diagnosis Of Schizophrenia Improves Results Of Treatment

Date:
February 27, 2004
Source:
Yale University
Summary:
Detecting and treating schizophrenia rapidly, following the onset of a first psychotic episode, improves the patients' response to treatment, according to a study by a Yale researcher.

New Haven, Conn. -- Detecting and treating schizophrenia rapidly, following the onset of a first psychotic episode, improves the patients' response to treatment, according to a study by a Yale researcher.

Thomas McGlashan, M.D., professor of psychiatry at Yale School of Medicine, said the length of time between the onset of psychosis and detection and treatment can stretch from several weeks to several years. This time span is a concern because the patient is sick and untreated and because there is some indication that the untreated psychotic state itself may increase the risk of a poor outcome.

"It looks like the longer the period of time before treatment, the worse off the patients are not only when they come into treatment, but how they respond to treatment," McGlashan said.

In a study published this month in the Archives of General Psychiatry, McGlashan looked at 281 patients in four Scandanavian health sectors with equivalent treatment programs. Two of the four sectors had early detection programs and two did not. Those that did have programs educated residents, school counselors, and health care workers about psychotic symptoms such as increasing isolation, responding to voices no one else hears, delusional thinking, irritability, difficulty sleeping, and overall marked reduction in the ability to cope with life's daily stresses.

Participants were followed up after three months, one year and two years. This study compares the patients' clinical state at admission and at the three month follow up. The researchers found that the duration of untreated patient psychosis in the two health sectors with early detection programs was significantly shorter -- one month as compared to four months.

"All factors being equal, early detection efforts will bring people into treatment at lower symptom levels," McGlashan said. "Patients who began treatment earlier tended to be younger, less symptomatic, and more responsive to treatment."

He said there will be a follow up after one, two , five and 10 years to see if the early detection and intervention has a lasting effect.

Co-authors included Ingrid Melle, M.D., Svein Friis, M.D., Stein Opjordsmoen, M.D., Bjorn Roshovd Rund, Per Vaglum, M.D., Tor Larsen, M.D., Jan Olav Johannessen, M.D., Ulrik Haahr, M.D., and Erik Simonsen, M.D.

Citation: Archives of General Psychiatry, 61:143-150.


Story Source:

The above story is based on materials provided by Yale University. Note: Materials may be edited for content and length.


Cite This Page:

Yale University. "Earlier Diagnosis Of Schizophrenia Improves Results Of Treatment." ScienceDaily. ScienceDaily, 27 February 2004. <www.sciencedaily.com/releases/2004/02/040227073039.htm>.
Yale University. (2004, February 27). Earlier Diagnosis Of Schizophrenia Improves Results Of Treatment. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2004/02/040227073039.htm
Yale University. "Earlier Diagnosis Of Schizophrenia Improves Results Of Treatment." ScienceDaily. www.sciencedaily.com/releases/2004/02/040227073039.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins